In a subgroup analysis of a phase 3, randomized, double-blind, active-controlled study, researchers compared the efficacy of subcutaneous LDP/CDP with oral LD/CD across subgroups of patients with advanced PD.

Researchers sought to establish the long-term results for the effectiveness and safety of CBD in patients with treatment-resistant epilepsy.

Researchers sought to assess the gaps in acute treatment optimization of migraine among participants from the CaMEO-I study.

In a retrospective analysis, researchers evaluated the effect of DMT discontinuation on risk for disease activity in MS.

In a post-hoc analysis, researchers determined the safety and efficacy of fremanezumab in patients with migraine and obesity.

In a phase 3, double-blind, multi-center, randomized-controlled trial, researchers evaluated the safety and efficacy of AXS-05 in AD-related agitation.

In a post-hoc analysis of a phase 3 trial, researchers determined the effect of RNA interference therapeutic vutrisiran on hATTR amyloidosis with polyneuropathy.

Researchers evaluated the safety and efficacy of subcutaneous efgartigimod PH20 in patients with chronic inflammatory demyelinating polyneuropathy.

Researchers examined the relationship between exposure to anti-inflammatory therapy and the incidence of Parkinson disease in patients with autoimmune conditions.

Researchers examined the effects of ataluren on clinically meaningful milestones that measure disease progression in patients with Duchenne muscular dystrophy.